Recovery support for post-injury repair protocols combining local tissue restoration and systemic recovery.
BPC-157 / TB-500 is part of the Mital clinical catalog as a stack-focused entry with standardized preparation, dosing, and quality-control guidance.
| Component | Amount (mg) |
|---|---|
| BPC-157 | 2.5 |
| TB-500 | 2.5 |
Mechanism of Action - Recovery & Tissue Repair Pathway
Use physician-guided initiation, titration, and maintenance phases aligned with response, tolerability, and objective biomarkers.
| Period | Dose | Phase | Clinical Notes |
|---|---|---|---|
| Weeks 1-2 | Initial phase | initiation | Begin conservatively and monitor tolerance. |
| Weeks 3-6 | Escalation phase | escalation | Increase per protocol if tolerated. |
| Week 7+ | Maintenance phase | maintenance | Maintain target dose and reassess monthly. |
Reconstitute with bacteriostatic water using aseptic handling. Inject diluent slowly along the vial wall and swirl gently until fully dissolved.
| Dose | Units to Draw | Volume (mL) | Approx. Supply |
|---|---|---|---|
| Half protocol dose | 50 | 1.00 | 4 injections |
| Full protocol dose | 100 | 2.00 | 2 injections |
Identity
- Product Name: BPC-157 / TB-500
- Strength Options: 5/5 mg, 10/10 mg
Quality & Purity
- Purity: >= 99%
- Sterility: Aseptic handling required
Storage & Handling
- Storage: 2-8 C refrigerated
- Handling: Avoid heat, shaking, and direct light
Timing: Use consistent administration timing for stable protocol tracking.
Storage: Store refrigerated at 2-8 C and protect from heat and light.
Frequency: Frequency follows protocol phase and physician direction.
Cycle: Cycle length and cadence are clinician-defined per patient profile.
Injection Sites: Rotate approved injection sites to reduce local irritation risk.